专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010091373A3 TRIMERICH HIV FUSION INHIBITORS FOR TREATING OR PREVENTING HIV INFECTION 审中-公开
标题翻译： TRIMERICH艾滋病毒融合抑制剂治疗或预防艾滋病毒感染
公开(公告)号：WO2010091373A3
公开(公告)日：2010-09-30
申请号：PCT/US2010023522
申请日：2010-02-08
申请人： NEW YORK BLOOD CT INC , JIANG SHIBO , QI ZHI , CHEN XI , PAN CHUNGEN
发明人： JIANG SHIBO , QI ZHI , CHEN XI , PAN CHUNGEN
IPC分类号： A61K38/17 , A61P31/18
CPC分类号： A61K38/162 , A61K38/00 , C07K14/005 , C07K2319/735 , C12N7/00 , C12N2740/16022 , C12N2740/16033 , C12N2740/16111 , C12N2740/16122
摘要： Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1 ) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.
摘要翻译：本文公开了包含三种单体的三聚体多肽药物组合物，每种单体包含具有人类跨膜糖蛋白的N-末端七肽重复（NHR或HR1）或C-末端七重复重复（CHR或HR2）的氨基酸序列的多肽免疫缺陷病毒（HIV）和三聚体基序。

2. 发明申请

WO2008148018A3 RAPIDLY DISPERSIBLE VAGINAL TABLET THAT PROVIDES A BIOADHESIVE GEL 审中-公开
公开(公告)号：WO2008148018A3
公开(公告)日：2008-12-04
申请号：PCT/US2008/064737
申请日：2008-05-23
申请人： NEW YORK BLOOD CENTER INC. , STONE, Alan , NEURATH, Alexander, Robert , STRICK, Nathan , JIANG, Shibo
发明人： STONE, Alan , NEURATH, Alexander, Robert , STRICK, Nathan , JIANG, Shibo
IPC分类号： A61K9/20 , A61K31/00
摘要： A tablet for insertion into a vagina including 0.01 to 500 mg of a vaginal medication, such as a microbicide, such as cellulose acetate 1,2- benzenedicarboxylate (CAP); 100 to 500 mg of mannitol powder; 50 to 300 mg of inert microcrystalline cellulose; 10 to 80 mg of hydroxypropyl methylcellulose; 50 to 250 mg of glycerol and optionally 2 to 4 mg of at least one preservative which protects against microbicidal contamination and discourages the growth of yeast in the vagina. The tablet which includes CAP as the vaginal medication is vaginally administered before coitus in methods for preventing the sexual transmission of HIV- 1, HIV-2, herpesvirus, or an infection caused by Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, Haemophilus ducreyi or Treponema pallidum. The tablet which includes CAP as the vaginal medication is vaginally administered to prevent or treat bacterial vaginosis.

3. 发明申请

WO2005120565A8 SARS VACCINES AND METHODS TO PRODUCE HIGHLY POTENT ANTIBODIES 审中-公开
标题翻译： SARS疫苗和生产高度抗体的方法
公开(公告)号：WO2005120565A8
公开(公告)日：2006-02-09
申请号：PCT/US2005019266
申请日：2005-06-01
申请人： NEW YORK BLOOD CT INC , JIANG SHIBO , HE YUXIAN , LIU SHUWEN
发明人： JIANG SHIBO , HE YUXIAN , LIU SHUWEN
IPC分类号： A61K39/00 , A61K39/215 , C07K14/165
CPC分类号： C07K14/005 , A61K39/00 , C07K2319/30 , C12N2770/20022
摘要： This invention provides a vaccine comprising an effective amount of an isolated polypeptide or recombinant protein containing the sequence of the receptor-binding domain in the SARS associated coronavirus spike protein or a functional fragment thereof, or a nucleic acid molecule comprising the sequence of a fragment which encodes the sequence of the receptor-binding domain in the Severe Acute Respiratory Syndrome associated coronavirus spike protein or a functional fragment thereof. This invention provides a composition for increasing the immunogenicity of an antigen comprising an effective amount of an antigen and an IgG Fc domain, its functional fragment, or a substance containing an IgG Fc domain or its functional fragment. The antigen and the IgG Fc may be linked or unlinked. Finally, this invention also provides method for using any of the above compositions for immunization.
摘要翻译：本发明提供一种疫苗，其包含有效量的分离的多肽或重组蛋白，其含有SARS相关冠状病毒穗状蛋白或其功能片段中受体结合结构域的序列，或包含该片段的序列的核酸分子编码重症急性呼吸综合征相关冠状病毒穗蛋白或其功能片段中受体结合结构域的序列。本发明提供用于增加抗原的免疫原性的组合物，其包含有效量的抗原和IgG Fc结构域，其功能片段或含有IgG Fc结构域或其功能片段的物质。抗原和IgG Fc可以连接或未连接。最后，本发明还提供了使用任何上述组合物进行免疫的方法。

4. 发明申请

WO2006086561A3 NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME-ASSOCIATED CORONAVIRUS 审中-公开
公开(公告)号：WO2006086561A3
公开(公告)日：2006-08-17
申请号：PCT/US2006/004599
申请日：2006-02-08
申请人： NEW YORK BLOOD CENTER , JIANG, Shibo , HE, Yuxian
发明人： JIANG, Shibo , HE, Yuxian
IPC分类号： A61K39/00 , A61K39/395 , A61K39/42 , A61K39/215
摘要： The present invention provides an isolated antibody capable of binding to the receptor- binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS- CoV S protein.

5. 发明申请

WO2005120565A2 SARS VACCINES AND METHODS TO PRODUCE HIGHLY POTENT ANTIBODIES 审中-公开
标题翻译： SARS疫苗和生产高度抗体的方法
公开(公告)号：WO2005120565A2
公开(公告)日：2005-12-22
申请号：PCT/US2005/019266
申请日：2005-06-01
申请人： NEW YORK BLOOD CENTER , JIANG, Shibo , HE, Yuxian , LIU, Shuwen
发明人： JIANG, Shibo , HE, Yuxian , LIU, Shuwen
IPC分类号： A61K39/215
CPC分类号： C07K14/005 , A61K39/00 , C07K2319/30 , C12N2770/20022
摘要： This invention provides a vaccine comprising an effective amount of an isolated polypeptide or recombinant protein containing the sequence of the receptor-binding domain in the SARS associated coronavirus spike protein or a functional fragment thereof, or a nucleic acid molecule comprising the sequence of a fragment which encodes the sequence of the receptor-binding domain in the Severe Acute Respiratory Syndrome associated coronavirus spike protein or a functional fragment thereof. This invention provides a composition for increasing the immunogenicity of an antigen comprising an effective amount of an antigen and an IgG Fc domain, its functional fragment, or a substance containing an IgG Fc domain or its functional fragment. The antigen and the IgG Fc may be linked or unlinked. Finally, this invention also provides method for using any of the above compositions for immunization.
摘要翻译：本发明提供一种疫苗，其包含有效量的分离的多肽或重组蛋白，其含有SARS相关冠状病毒穗状蛋白或其功能片段中受体结合结构域的序列，或包含该片段的序列的核酸分子编码重症急性呼吸综合征相关冠状病毒穗蛋白或其功能片段中受体结合结构域的序列。本发明提供用于增加抗原的免疫原性的组合物，其包含有效量的抗原和IgG Fc结构域，其功能片段或含有IgG Fc结构域或其功能片段的物质。抗原和IgG Fc可以连接或未连接。最后，本发明还提供了使用任何上述组合物进行免疫的方法。

6. 发明申请

WO2004047730A2 COMPOUNDS FOR INHIBITION OF HIV INFECTION BY BLOCKING HIV ENTRY 审中-公开
标题翻译：通过阻止艾滋病毒入侵来抑制艾滋病毒感染的化合物
公开(公告)号：WO2004047730A2
公开(公告)日：2004-06-10
申请号：PCT/US0336359
申请日：2003-11-12
申请人： NEW YORK BLOOD CT INC , JIANG SHIBO , DEBNATH ASIM KUMAR
发明人： JIANG SHIBO , DEBNATH ASIM KUMAR
IPC分类号： A61K20060101 , A61K31/40 , C07D207/30 , C07D207/32 , C07D207/327 , C07D413/04 , C07D417/04 , A61K
CPC分类号： C07D207/327
摘要： A group of compounds that inhibit HIV replication by blocking HIV entry was identified. Two representative compounds, designated NB-2 and NB-64, inhibited HIV replication (p24 production) with IC50 values
摘要翻译：鉴定了一组通过阻断HIV进入而抑制HIV复制的化合物。两种代表性的化合物（称为NB-2和NB-64）抑制HIV复制（p24产生），IC50值<0.5 mug / ml。证明NB-2和NB-64是通过靶向HIV gp41的HIV进入抑制因子，因为：1）它们抑制HIV介导的细胞融合; 2）只有当病毒加入不到1小时后，才能抑制HIV复制; 3）它们不阻断gp120-CD4结合; 4）它们没有与共受体CXCR4相互作用，因为它们不能阻断抗CXCR4抗体结合CXCR4表达细胞; 5）它们阻断了使用构象特异性Mab NC-1通过夹心酶联免疫吸附测定（ELISA）检测到的gp41核心的形成; 6）它们抑制荧光天然 - 聚丙烯酰胺凝胶电泳（FN-PAGE）显示的gp41六螺旋束的形成; 和7）它们阻断了肽肽与肽IQN17模拟的gp41卷曲螺旋结构域内的疏水空穴的结合。这些结果表明NB-2和NB-64可能与疏水腔相互作用并阻断融合活性gp41卷曲螺旋结构域的形成，导致HIV-1介导的膜融合和病毒进入的抑制。

7. 发明申请

WO2010091373A8 TRIMERIC HIV FUSION INHIBITORS FOR TREATING OR PREVENTING HIV INFECTION 审中-公开
标题翻译： TRIMERIC艾滋病毒融合抑制剂治疗或预防艾滋病毒感染
公开(公告)号：WO2010091373A8
公开(公告)日：2011-07-07
申请号：PCT/US2010023522
申请日：2010-02-08
申请人： NEW YORK BLOOD CT INC , JIANG SHIBO , QI ZHI , CHEN XI , PAN CHUNGEN
发明人： JIANG SHIBO , QI ZHI , CHEN XI , PAN CHUNGEN
IPC分类号： A61K38/17 , A61P31/18
CPC分类号： A61K38/162 , A61K38/00 , C07K14/005 , C07K2319/735 , C12N7/00 , C12N2740/16022 , C12N2740/16033 , C12N2740/16111 , C12N2740/16122
摘要： Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1 ) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.
摘要翻译：本文公开了包含三种单体的三聚体多肽药物组合物，每种单体包含具有人类跨膜糖蛋白的N-末端七肽重复（NHR或HR1）或C-末端七重复重复（CHR或HR2）的氨基酸序列的多肽免疫缺陷病毒（HIV）和三聚体基序。

8. 发明申请

WO2005120565A3 SARS VACCINES AND METHODS TO PRODUCE HIGHLY POTENT ANTIBODIES 审中-公开
标题翻译： SARS疫苗和生产高度抗体的方法
公开(公告)号：WO2005120565A3
公开(公告)日：2007-05-18
申请号：PCT/US2005019266
申请日：2005-06-01
申请人： NEW YORK BLOOD CT INC , JIANG SHIBO , HE YUXIAN , LIU SHUWEN
发明人： JIANG SHIBO , HE YUXIAN , LIU SHUWEN
IPC分类号： A61K39/215 , A61K39/00 , C07K1/00 , C07K14/165
CPC分类号： C07K14/005 , A61K39/00 , C07K2319/30 , C12N2770/20022
摘要： This invention provides a vaccine comprising an effective amount of an isolated polypeptide or recombinant protein containing the sequence of the receptor-binding domain in the SARS associated coronavirus spike protein or a functional fragment thereof, or a nucleic acid molecule comprising the sequence of a fragment which encodes the sequence of the receptor-binding domain in the Severe Acute Respiratory Syndrome associated coronavirus spike protein or a functional fragment thereof. This invention provides a composition for increasing the immunogenicity of an antigen comprising an effective amount of an antigen and an IgG Fc domain, its functional fragment, or a substance containing an IgG Fc domain or its functional fragment. The antigen and the IgG Fc may be linked or unlinked. Finally, this invention also provides method for using any of the above compositions for immunization.
摘要翻译：本发明提供一种疫苗，其包含有效量的分离的多肽或重组蛋白，其含有SARS相关冠状病毒穗状蛋白或其功能片段中受体结合结构域的序列，或包含该片段的序列的核酸分子编码重症急性呼吸综合征相关冠状病毒穗蛋白或其功能片段中受体结合结构域的序列。本发明提供用于增加抗原的免疫原性的组合物，其包含有效量的抗原和IgG Fc结构域，其功能片段或含有IgG Fc结构域或其功能片段的物质。抗原和IgG Fc可以连接或未连接。最后，本发明还提供了使用任何上述组合物进行免疫的方法。

9. 发明申请

WO2004047730A3 COMPOUNDS FOR INHIBITION OF HIV INFECTION BY BLOCKING HIV ENTRY 审中-公开
公开(公告)号：WO2004047730A3
公开(公告)日：2004-06-10
申请号：PCT/US2003/036359
申请日：2003-11-12
申请人： NEW YORK BLOOD CENTER , JIANG, Shibo , DEBNATH, Asim, Kumar
发明人： JIANG, Shibo , DEBNATH, Asim, Kumar
IPC分类号： C07D207/30
摘要： Compounds that inhibit HIV replication by blocking HIV entry was identified.

10. 发明申请

WO1998030716A1 METHODS FOR SCREENING OF TEST COMPOUNDS FOR INHIBITING BINDING OF A CD4-HIV-1 COMPLEX TO HIV-1 SECOND RECEPTORS 审中-公开
标题翻译：用于筛选用于抑制CD4-HIV-1复合物与HIV-1第二受体结合的测试化合物的方法
公开(公告)号：WO1998030716A1
公开(公告)日：1998-07-16
申请号：PCT/US1997023958
申请日：1997-12-31
申请人： NEW YORK BLOOD CENTER , NEURATH, Alexander, Robert , JIANG, Shibo , DEBNATH, Asim, Kumar , LI, Yun-Yao , STRICK, Nathan
发明人： NEW YORK BLOOD CENTER
IPC分类号： C12Q01/00
CPC分类号： G01N33/56988
摘要： A method for the screening of a test compound for inhibiting the binding of a CD4-HIV-1 complex to HIV-1 second receptors, comprising: (a) preparing a magnetic ligand by mixing a magnetic, CD4-containing substrate with HIV-1, (b) mixing the magnetic ligand from step (a) with a test compound, (c) adding cells that express the HIV-1 second receptors to the mixture from step (b), (d) separating cells with bound magnetic ligands from cells without bound magnetic ligands by contact with a magnetic separator, and (e) quantifying the cells with bound magnetic ligands and quantifying the cells without bound magnetic ligands.
摘要翻译：用于筛选用于抑制CD4-HIV-1复合物与HIV-1第二受体结合的测试化合物的方法，包括：（a）通过将含磁性的含CD4底物与HIV-1混合来制备磁性配体（b）将来自步骤（a）的磁性配体与测试化合物混合，（c）将来自步骤（b）的混合物中表达HIV-1第二受体的细胞加入到（d）通过与磁选机接触而无结合的磁性配体的细胞，和（e）用结合的磁性配体定量细胞并定量没有结合的磁性配体的细胞。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式